Financial Performance - Revenue for Q1 2025 was CNY 225,002,020.97, a decrease of 0.57% compared to CNY 226,302,459.95 in the same period last year[5] - Net profit attributable to shareholders was CNY 43,768,169.85, down 6.54% from CNY 46,831,857.32 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.1930, reflecting a decrease of 6.54% compared to CNY 0.2065 in the prior year[5] - Total operating revenue for the current period was ¥225,002,020.97, a decrease of 0.57% from ¥226,302,459.95 in the previous period[18] - Net profit for the current period was ¥43,723,532.62, down 6.4% from ¥46,793,784.04 in the previous period[19] - The total comprehensive income for the current period is CNY 43,723,532.62, compared to CNY 46,793,784.04 in the previous period, reflecting a decrease of approximately 4.5%[20] Cash Flow - Net cash flow from operating activities improved significantly to CNY 21,232,808.69, a 281.18% increase from a negative CNY 11,719,385.39 in the previous year[5] - Cash inflows from operating activities totaled CNY 266,502,826.78, an increase of approximately 16.9% from CNY 227,799,769.87 in the previous period[22] - Cash inflows from investing activities amounted to CNY 55,360,205.56, while cash outflows were CNY 30,351,184.34, resulting in a net cash flow of CNY 25,009,021.22, compared to a net outflow of CNY 46,345,234.02 in the previous period[22] - Cash inflows from financing activities were CNY 100,000,000.00, down from CNY 154,378,416.90 in the previous period, reflecting a decrease of about 35.2%[22] - The net cash flow from financing activities is -CNY 15,911,820.57, a significant decline compared to a net inflow of CNY 142,930,683.34 in the previous period[22] - The ending cash and cash equivalents balance is CNY 305,060,446.40, down from CNY 336,343,535.12 in the previous period, indicating a decrease of approximately 9.3%[22] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 3,290,684,004.06, a slight decrease of 0.21% from CNY 3,297,444,233.19 at the end of the previous year[5] - Total liabilities decreased to ¥1,002,724,006.27 from ¥1,053,207,768.02, a reduction of 4.8%[16] - The company's equity attributable to shareholders increased to ¥2,255,193,500.99 from ¥2,211,425,331.14, an increase of 1.97%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,540[10] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares[10] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 1,197,892.46, contributing positively to the financial results[7] - Other income increased by 44.79% to CNY 2,284,038.25, primarily due to an increase in government subsidies received[8] - Research and development expenses were ¥11,551,806.32, down 5.5% from ¥12,223,999.54 in the previous period[19] - The company reported a credit impairment loss of ¥343,987.15, compared to a loss of ¥503,396.46 in the previous period[19] Accounting and Audit - The company has not undergone an audit for the first quarter report[23] - The company will implement new accounting standards starting from 2025[24]

Financial Performance - The company's operating revenue for 2024 reached ¥1,203,192,257.65, representing a 14.75% increase compared to ¥1,048,502,589.77 in 2023[21] - The net profit attributable to shareholders for 2024 was ¥253,516,220.45, up 15.95% from ¥218,651,341.25 in 2023[21] - The net profit after deducting non-recurring gains and losses was ¥263,514,572.94, reflecting a 25.97% increase from ¥209,192,977.37 in 2023[21] - The basic earnings per share for 2024 was ¥1.1178, a 15.94% increase from ¥0.9641 in 2023[21] - The total assets at the end of 2024 amounted to ¥3,297,444,233.19, a 14.62% increase from ¥2,876,778,757.84 at the end of 2023[21] - The company's cash flow from operating activities decreased by 55.33% to ¥177,765,211.48 from ¥397,938,765.23 in 2023[21] - The weighted average return on equity for 2024 was 11.99%, up from 11.37% in 2023[21] - The company achieved a historical high in revenue for 2024, reaching approximately CNY 1.203 billion, a year-on-year increase of 14.75%[46] Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥2 per 10 shares, totaling ¥45,360,000 based on 226,800,000 shares[7] - The total number of shares for the dividend distribution is based on 226,800,000 shares, with a distributable profit of 1,226,520,067.15 CNY[141] - The company has implemented a third employee stock ownership plan, with 787,000 shares purchased, accounting for 0.35% of the total share capital[144] - The cash dividend policy is compliant with the company's articles of association and has clear standards and procedures[140] Market and Industry Trends - The blood products industry in China is expected to see a significant increase in per capita demand due to aging population trends and improved healthcare resources[34] - The market for blood products is projected to grow as the number of patients increases and the usage rates of immunoglobulins and albumin rise[33] - The blood products industry faces high entry barriers and strict regulatory oversight, limiting the number of operational companies in the market[32] - The blood product industry is experiencing ongoing consolidation, with the top five companies holding a significant market share, indicating a trend towards increased industry concentration[37] Product Development and R&D - The company aims to enhance the comprehensive utilization rate of plasma through continuous product research and development[35] - The company is focusing on developing recombinant products to supplement blood-derived products, which are limited by plasma supply[36] - The company is developing new products, including a prothrombin complex concentrate (PCC) expected to enhance product variety and improve plasma utilization rates[67] - The company holds 64 patents, including 24 invention patents, reflecting its strong commitment to research and development in the biopharmaceutical sector[50] Operational Efficiency and Management - The company is focusing on improving quality management efficiency through the implementation of nine projects, including a quality management system and AI video monitoring[94] - The company aims to enhance its core competitiveness through four major actions: scale, efficiency, effectiveness, and market value improvements[92] - The company plans to implement a strategy to increase plasma source development and improve internal management to enhance plasma collection quality and service levels[93] Risks and Challenges - The company has highlighted potential risks in its future operations, which investors should be aware of[5] - The company faces risks related to insufficient raw plasma supply due to stricter regulations on establishing new plasma collection stations[98] - The company faces risks in new product development due to long research cycles influenced by technology, design, clinical outcomes, budget, policies, and market demand[99] - Potential safety risks exist in blood products due to unknown pathogens, despite strict adherence to national regulations and advanced collection technologies[100] Governance and Leadership - The company maintains a robust governance structure, ensuring independence from its controlling shareholder in operations, finance, and assets[109] - The company experienced a leadership change with the resignation of Vice General Manager Xu Qiang due to retirement on August 21, 2024[115] - The company is in the process of nominating candidates for the new board of directors and supervisory board, with the election postponed to ensure continuity[114] - The company’s chairman, Zhang Zhan, has been in position since December 2021, ensuring stable leadership[117] Environmental Responsibility - The company has complied with various environmental protection laws and regulations, ensuring adherence to industry standards[152] - The company has successfully obtained environmental impact assessments and permits for its production facilities, with valid licenses extending to 2027[153] - The company has achieved ISO14001 environmental management system certification in 2021 and successfully passed recertification in 2024, promoting low-carbon and energy-saving initiatives[159] Employee and Community Engagement - The company has provided various employee benefits, including social insurance, housing funds, and annual health check-ups[136] - The training program for employees has been executed well, focusing on corporate culture, professional skills, and management capabilities, although improvements are needed in coverage and relevance[137] - The company has engaged in social responsibility activities, with approximately 150 registered volunteers participating in 9 events, contributing over 200 volunteer service hours[160]

证券代码:002880 证券简称:卫光生物 公告编号:2025-003 深圳市卫光生物制品股份有限公司 第三届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第三十二 次会议于2025年4月21日在公司综合楼三楼会议室以现场结合通讯方式召开。本 次会议应参加董事8名，实际参加董事8名，公司监事及高级管理人员列席了会议。 本次会议由董事长张战先生主持，会议的召集、召开和表决程序符合《公司法》 等有关法律、法规及《公司章程》的规定。 与会董事认真听取了公司总经理所作的《2024年度总经理工作报告》，认为 该报告客观、真实地反映了2024年度公司落实股东大会及董事会决议、管理生产 经营、执行公司各项管理制度等方面工作的情况。 二、董事会会议审议情况 会议经逐项审议，书面表决，审议通过了以下议案： 1.审议通过了《关于2024年年度报告及其摘要的议案》； 公司《2024年年度报告》及其摘要具体内容详见同日刊登在指定信息披露媒 体及巨潮资讯网(www.cnin ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-006 深圳市卫光生物制品股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 深圳市卫光生物制品股份有限公司（以下简称公司）于 2025 年 4 月 21 日召 开第三届董事会第三十二次会议、第三届监事会第二十五次会议，审议通过了《关 于 2024 年度利润分配预案的议案》，上述议案尚需提交公司 2024 年度股东大会 审议。现将该预案有关情况公告如下： 二、利润分配方案的基本情况 根据大信会计师事务所（特殊普通合伙）出具的 2024 年度审计报告，2024 年，公司实现合并报表归属于上市公司普通股股东净利润 253,516,220.45 元，母 公司报表净利润 245,437,546.46 元。根据《公司章程》的相关规定，公司分配当 年税后利润时，应当提取利润的 10%列入公司法定公积金。公司法定公积金累计 额为公司注册资本的 50%以上的，可以不再提取。2024 年度，公司提取法定公 积金 24,543,754.65 元。公司 2 ...

对水质品讨论比较多想请金总帮我们再更新一下行业过去一年的变化因为我们知道去年其实上半年的价格不算特别稳定到下半年会好一些那么第二个是想一起探讨一下这个加征关税之后对法轮白行业的供给格局的变化金总 大家好,我是温哥华生活纪念营 非常荣幸接受国联的邀请跟大家做一个简单的分享当然我讲的不一定对只是个人的一点简单的体会大家可能对现在加征这个34%的关税的这个事情这两天都非常热门大家相互聊的可能也比较多大家交流的也挺多今天我只是站在我个人 好的 没问题 在这里我想跟大家分享一些行业的一些信息给大家做一些参考第一个我是觉得这两天大家对于进口白蛋白的加税的事情可能有些误解上面的东西我觉得跟大家一起做一些分享第一点就是 目前加税只是针对于美国产地的这一部分那么目前在国内市场上其实进口白斩白斩其实就有好几个产地那么四大家的这个主要的这个进口商实际上他们每一个厂都有好几个产地美国产地只是其中的一部分所以我这个第一个角度我是觉得希望大家能够理解 就是对于进口白量白加税这件事情其实我们要更加理性的来看待因为这个范围目前只是针对美国产地的这一部分那么据我大概从PCR的数据方面的了解和分析目前来说进口的白量白占国内的总的PCR量大概在6 ...

Q&A 过去一年血制品行业的变化以及加征关税对白蛋白行业供给格局的影响是什 么？ 去年（2024 年）上半年白蛋白价格不算特别稳定，下半年情况有所好转。加征 关税后，进口白蛋白市场出现了一些变化。目前加税仅针对美国产地的部分， 而国内市场上的进口白蛋白来自多个产地。根据数据分析，进口白蛋白占国内 批签发量约 65%，其中美国产地约占 15%到 20%。去年年底，各血制品厂商采取 了降价策略以争夺市场，导致库存水平较高，估计有五六个月的库存量，总库 • 国内白蛋白市场受多重政策压力影响，包括医保控费、医院控量和集采等， 导致供应商采取降价或稳价策略以保市场份额，短期内涨价动力不足。若 国家政策倾斜于战略性产品，将有利于血制品行业发展。 • 加征关税对进口美国白蛋白价格的直接影响有限，因国内外市场价格存在 显著差距（美国 1.7 美元/克，中国 30 美元/克），海外厂商可通过调整价 格结构来抵消 34%的关税影响。 • 海外厂商在国内的出厂价格（约 3 美元/克）高于海外价格（2-2.5 美元/ 克），集采政策可能促使外资品牌减少对中国市场的重视，从而加速国产 替代进程。国内血液制品增速保持在 15%左右，为国 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2025-002 深圳市卫光生物制品股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况 深圳市卫光生物制品股份有限公司（以下简称公司）股票交易价格单个交易日（2025年4月7日）收盘价 涨幅偏离值超过20%，根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动的情况。 二、公司关注及核实情况说明 针对股票交易异常波动的情况，公司进行了必要的核实，现将有关情况说明如下： 1.公司前期所披露的信息不存在需要更正、补充之处； 2.公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息； 3.公司及控股股东、实际控制人不存在关于公司的应披露而未披露的重大事项，或处于筹划阶段的重大 事项； 4.控股股东、实际控制人在股票交易异常波动期间不存在买卖公司股票的情形。 三、是否存在应披露而未披露信息的说明 公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市规则》等 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-002 深圳市卫光生物制品股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股票交易异常波动的情况 三、是否存在应披露而未披露信息的说明 公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议 等；董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》等有关规定应 予以披露而未披露的、对本公司股票交易价格产生较大影响的信息；公司前期披露 的信息不存在需要更正、补充之处。 四、风险提示 1. 经自查，公司不存在违反公平信息披露的情形； 深圳市卫光生物制品股份有限公司（以下简称公司）股票交易价格单个交易日 （2025年4月7日）收盘价涨幅偏离值超过20%，根据《深圳证券交易所交易规则》 的有关规定，属于股票交易异常波动的情况。 二、公司关注及核实情况说明 针对股票交易异常波动的情况，公司进行了必要的核实，现将有关情况说明如 下： 1. 公司前期所披露的信息不存在需要更正、补充 ...

第三期员工持股计划 （草案）摘要（二次修订稿） 二〇二四年十二月 1 声明 本公司及公司董事会全体成员保证本员工持股计划不存在虚假记载、 误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的 法律责任。 2 深圳市卫光生物制品股份有限公司 风险提示 （五）股票价格受公司经营业绩、宏观经济周期、国际/国内政治经济形 势及投资者心理等多种复杂因素影响。因此，股票交易是有一定风险的投资 活动，投资者对此应有充分准备； （六）敬请广大投资者谨慎决策，注意投资风险。 3 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 1、深圳市卫光生物制品股份有限公司第三期员工持股计划（以下简称"本员 工持股计划"或"本持股计划"）系依据《中华人民共和国公司法》、《中华人民共 和国证券法》、《关于上市公司实施员工持股计划试点的指导意见》等有关法律、 行政法规、规章、规范性文件和《公司章程》的规定制定。 2、本员工持股计划遵循依法合规、自愿参与、风险自担的原则，不存在摊 派、强行分配等强制员工参加本员工持股计划的情形。 3、本员工持股计划设立后将由公司自行管理，员工持股计划主要投资范围 为卫光生物 A 股普通股股 ...

第一条 为规范深圳市卫光生物制品股份有限公司(以下简称"卫光生物" 或"公司") 第三期员工持股计划(以下简称"本员工持股计划") 的实施， 根据 《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》 (以下简称"《证券法》")、《关于上市公司实施员工持股计划试点的指导意见》 (以下简称"《指导意见》")等相关法律、行政法规、规章、规范性文件和《公 司章程》之规定，特制定本管理办法。 第二条 员工持股计划所遵循的基本原则 (一) 依法合规原则 公司实施本员工持股计划， 严格按照法律、行政法规的规定履行程序， 真实、 准确、完整、及时地实施信息披露。任何人不得利用员工持股计划进行内幕交易、 操纵证券市场等证券欺诈行为。 (二) 自愿参与原则 公司实施本员工持股计划遵循公司自主决定， 员工自愿参加的原则， 公司不 以摊派、强行分配等方式强制员工参加本员工持股计划。 (三) 风险自担原则 本员工持股计划参与人盈亏自负，风险自担，与其他投资者权益平等。 第三条 员工持股计划履行的程序 1、公司实施本员工持股计划前，应通过职工代表大会等组织充分征求员工 意见； 2、董事会审议通过本员工持股计划草 ...